hotspot -WSS

hotspot

author：knowledge 2025-09-27 11:58:15 - browse：69

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FogPharma raises $145 million in rare Series E round

leisure time

WSS

Why getting cancer drugs just got harder for rural patients

Congress gives doctors Medicare pay bump

Why 40% Americans with Parkinson’s don’t see a neurologist

Why 40% Americans with Parkinson’s don’t see a neurologist

NIH fellows want a pay raise. Will that mean less money for grants?

HCA discloses massive data breach affecting 11 million patients

hotspot

hotspot

The next ALS data readout — overdue but important

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Congress gives doctors Medicare pay bump

Cancer drug shortages should be causing more outrage

Flu vaccine offering decent levels of protection this winter, new data show

United colonoscopy coverage change 'may cost lives,' doctors say

California’s proposed $25 per hour health care minimum wage

As demand for Covid shots wanes, Moderna seeks its next success

How to address the problem of discarded donor organs

New air purifier tech could be key to improving indoor air quality

Kenai launches with $82 million for Parkinson’s stem cell therapy

focus

Iowa House, Senate pass 6

Study: Pain burden is higher in Black NFL players than white ones

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Palantir health business leans on meeting customers’ needs

Lecanemab for Alzheimer's is coming. Is the health system ready?

Covid isolation guidance eased by the CDC

leisure time

focus

leisure time

hotspot